Search tips
Search criteria 


Logo of bttDove Medical PressThis ArticleSubscribeSubmit a ManuscriptSearchFollowDovepressBiologics: Targets and Therapy
Biologics. 2012; 6: 125–134.
Published online Jun 5, 2012. doi:  10.2147/BTT.S31833
PMCID: PMC3379853
Pediatric ulcerative colitis: current treatment approaches including role of infliximab
Gia M Bradley and Maria Oliva-Hemker
Division of Pediatric, Gastroenterology and Nutrition, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Correspondence: Maria Oliva-Hemker, 600 N Wolfe Street, Brady 320, Baltimore, MD 21287-2631, USA, Tel +1 410 955 8769, Fax +1 410 955 1464, Email moliva/at/
Ulcerative colitis is a chronic inflammatory bowel disease that can lead to derangements in the growth, nutritional status, and psychosocial development of affected children. There are several medical options for the induction and maintenance of disease remission, but the benefits of these medications need to be carefully weighed against the risks, especially in the pediatric population. As the etiology of the disease has become increasingly understood, newer therapeutic alternatives have arisen in the form of biologic therapies, which are monoclonal antibodies targeted to a specific protein or receptor. This review will discuss the classical treatments for children with ulcerative colitis, including 5-aminosalicylates, corticosteroids, thiopurine immunomodulators, and calcineurin inhibitors, with a particular focus on the newer class of anti-tumor necrosis factor-α agents.
Keywords: 5-aminosalicylates, anti-tumor necrosis factor-α agents, corticosteroids, cyclosporine, inflammatory bowel disease, thiopurine immunomodulators
Articles from Biologics : Targets & Therapy are provided here courtesy of
Dove Press